Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 719

1.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168. Epub 2013 Apr 21.

PMID:
23601249
2.

Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T.

World J Gastroenterol. 2014 Sep 21;20(35):12581-7. doi: 10.3748/wjg.v20.i35.12581.

3.

Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.

Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH.

Gut Liver. 2013 Nov;7(6):696-703. doi: 10.5009/gnl.2013.7.6.696. Epub 2013 Aug 14.

4.

Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F.

World J Gastroenterol. 2014 Jan 21;20(3):786-94. doi: 10.3748/wjg.v20.i3.786.

5.

Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.

Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY.

BMC Cancer. 2015 Apr 8;15:236. doi: 10.1186/s12885-015-1273-2.

6.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM.

J Hepatol. 2012 Oct;57(4):821-9. doi: 10.1016/j.jhep.2012.06.014. Epub 2012 Jun 19.

7.
8.

Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.

Estfan B, Byrne M, Kim R.

Am J Clin Oncol. 2013 Aug;36(4):319-24. doi: 10.1097/COC.0b013e3182468039.

PMID:
22547010
9.

Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.

Li J, Wang L, Cong N, Shi C, Bu W, Song J, Chen H.

Hepatogastroenterology. 2014 Jun;61(132):954-7.

PMID:
26158148
10.

Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.

Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ, Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, Byun KS.

J Clin Gastroenterol. 2014 Mar;48(3):e22-9. doi: 10.1097/MCG.0b013e3182a54ec8.

PMID:
24045282
11.

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.

Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L.

Eur J Cancer. 2013 Nov;49(16):3412-9. doi: 10.1016/j.ejca.2013.05.028. Epub 2013 Jun 25.

12.

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.

Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.

PMID:
23182599
13.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators.

Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.

PMID:
26361969
14.

Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib.

Tsukui Y, Mochizuki H, Hoshino Y, Kawakami S, Kuno T, Fukasawa Y, Iwamoto F, Hirose S, Yoshida T, Hosoda K, Suzuki Y, Hosoda K, Kojima Y, Hirose Y, Shindou K, Matsuda M, Yagawa S, Tawara A, Kobayashi M, Konishi T, Yamazaki T, Takahashi S, Fuji H, Enomoto N, Omata M.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2536-9.

PMID:
22497953
15.

Sorafenib in liver function impaired advanced hepatocellular carcinoma.

Ji YX, Zhang ZF, Lan KT, Nie KK, Geng CX, Liu SC, Zhang L, Zhuang XJ, Zou X, Sun L, Zhang ZC.

Chin Med Sci J. 2014 Mar;29(1):7-14.

PMID:
24698672
16.

Sorafenib: from literature to clinical practice.

Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Verslype C.

Ann Oncol. 2013 Apr;24 Suppl 2:ii30-7. doi: 10.1093/annonc/mdt055. Review.

17.
18.

Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.

Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O.

Invest New Drugs. 2015 Jun;33(3):729-39. doi: 10.1007/s10637-015-0237-3. Epub 2015 Apr 12.

PMID:
25861764
19.

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.

Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhang ZL, Han GH.

Ann Oncol. 2013 Jul;24(7):1786-92. doi: 10.1093/annonc/mdt072. Epub 2013 Mar 18.

20.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.

J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.

PMID:
19247201
Items per page

Supplemental Content

Write to the Help Desk